Clinical outcomes of tricuspid valve repair accompanying left-sided heart disease

Table 3 Univariate analyses: Parameters affecting global mortality

Variable	n (%)	Univariate HR	P
Gender (male)	79 (44)	1.38 [0.77-2.44]	0.27
Age (≥ 75 yr)	63 (35)	1.75 [0.98-3.11]	0.06
Tobacco use	44 (24)	1.16 [0.60-2.24]	0.66
Pulmonary disease	25 (14)	1.58 [0.74-3.40]	0.24
Pacemaker	16 (9)	2.40 [1.12-5.13]	0.02
Branch block	40 (22)	1.88 [1.01-3.47]	0.04
Previous heart failure	75 (42)	1.67 [0.94-2.95]	0.08
Ejection fraction (> 50%)	132 (73)	0.49 [0.25-0.98]	0.044
Hypertension	79 (44)	1.81 [1.01-3.20]	0.04
Diabetes on insulin	8 (4)	2.33 [0.83-6.51]	0.11
Aortic regurgitation	19 (11)	0.52 [0.16-1.67]	0.27
Aortic disease	15 (8)	1.29 [0.51-3.26]	0.59
Mitral regurgitation	99 (55)	1.01 [0.56-1.79]	0.98
Mitral stenosis	21 (12)	0.96 [0.38-2.44]	0.93
Mitral disease	21 (12)	0.55 [0.19-1.54]	0.26
Dyslipidemia	77 (43)	0.88 [0.49-1.57]	0.67
NIDD	34 (19)	1.31 [0.64-2.64]	0.45
Cerebrovascular accident	19 (11)	1.44 [0.60-3.40]	0.41
Myocardial infarction	12 (7)	1.70 [0.67-4.30]	0.26
New York Heart Association (III/IV)	148 (82)	1.99 [0.78-5.04]	0.14
Redo vs Tridux	26 (14)	1.49 [0.74-3.00]	0.26
Double valve replacement associated with tricuspid repair	43 (24)	2.21 [1.11-4.39]	0.024
Sinus rhythm	77 (43)	0.74 [0.41-1.35]	0.33
Sovering ring	156 (87)	1.10 [0.49-2.46]	0.81
Bex device	20 (11)	1.16 [0.52-2.60]	0.71
Systolic pulmonary artery pressure (> 59 mmHg)	98 (54)	1.06 [0.60-1.88]	0.83
Systolic pulmonary artery pressure (> 49 mmHg)	31 (17)	1.16 [0.56-2.40]	0.69
Tricuspid annulus diameter (> 40 mm)	20 (11)	0.31 [0.07-1.27]	0.10
Postoperative ejection fraction (> 50%)	98 (66)	2.58 [1.31-5.08]	0.006

HR: Hazard ratio.